TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in the α angle of the tidal breathing CO2 waveform
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Minimum and maximum CO2 levels of the tidal breathing CO2 waveform
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Variability of breath length of the tidal breathing CO2 waveform
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Standard deviation of End Tidal CO2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Partial clinical remission time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Physical Health
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Unplanned Hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: World Health Organization Disability Assessment Scale (WHODAS) Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in mean intake of fruit and vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Survival at 30 Days
Endpoint domain: Mortality/survival
Primary endpoint: Survival at 90 Days
Endpoint domain: Mortality/survival
Primary endpoint: Change in Foot-Related pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of HD-related admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: PDSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes on cognitive functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Patients with a Minimum of 6 Months Follow-up by DMT Use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Patients with a Minimum of 12 Months Follow-up by DMT Use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Analgesia required
Endpoint domain: Adverse events/effects
Primary endpoint: Urinalysis negative for cocaine
Endpoint domain: Adverse events/effects
Primary endpoint: Mutation consistency of metastatic and primary sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent of patients with Numeric Pain Rating Score (NPRS) <1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patients with Numeric Pain Rating Score (NPRS) <3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: St Georges Respiratory Questionnaire (SGRQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life-Bronchiectasis (QOL-B) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Increase in aortic diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intensity of 18-FDG binding (Standard Uptake Value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in the Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym) Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Diagnostic quality of WB-MRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of swallowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Investigator Global Assessment of Participants' Response to Therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients with referral to a cardiology specialist
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients with blood pressure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with Cholesterol control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Asthma Control Test (ACT) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Hamilton Rating Scale for Depression (HAMD17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Binge drinking frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drinking problems
Endpoint domain: Adverse events/effects
Primary endpoint: Illicit drug use events
Endpoint domain: Adverse events/effects
Primary endpoint: Average Wake Time After Sleep Onset (WASO)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from baseline in epidermal hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to relapse of agitation symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disease-free survival at 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Time to improvement in body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to improvement in SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to improvement in chest imaging findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to improvement in negative SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Early successful recanalisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined Rhinoconjunctivitis Daily Symptom Score and Daily Medication Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total opioid consumption post-cesarean delivery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence and density of glistenings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enalapril concentration in blood serum (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjects With Any Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Hours to passage of last unformed stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Disease regression/progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of High-risk Residents According to the FRAiL Model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of High-risk Residents With One or More Deprescribing Recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attrition of Eligible Residents From the NH Facility Due to Transfer, Discharge to Community, or Death
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy of Treating Bleeding Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants Who Reported Substance Use at 6 Month
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of hematoma expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Symptomatic intracerebral haemorrhage after thrombolysis
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Weighted Mean FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the plasma concentration-time curve from zero to infinity for AZD1775
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to the time t (AUC0-t) of the last quantifiable concentration for AZD1775
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: maximum plasma drug concentration for AZD1775
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Crohns Disease Activity Index (CDAI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: laboratory-measured efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival (PFS) Rate at 18 months
Endpoint domain: Mortality/survival
Primary endpoint: number of respiratory tract infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: number of influenza cases defined as a RTI with positive nose and throat swabs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: number of influenza cases defined as a RTI with 4-fold IgG titre rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Global leg symptoms severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With at Least One Serious TEAE
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Without Retinal Fluid in the Center Subfield of Study Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Electromyographic activity of trunk erector muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Microscopic analyses of the marginal gap formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All cause morbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients undergoing Antegrade double-J stent placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Decision making ability of adolescent girls
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prescription rate of antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum Observed Plasma Concentration for Ixazomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach the Maximum Observed Plasma Concentration for Ixazomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time 0 to 312 Hrs Post-dose for Ixazomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Treatment Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Hypersensitivity Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Thromboembolic Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Splenectomy
Endpoint domain: Adverse events/effects
Primary endpoint: Survival at discharge day
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy of HyperAcute-Prostate (HAP) cancer cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of HyperAcute-Prostate (HAP) cancer cells
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Women With ≥1 Live Born Infant During Follow-up (Take-Home Baby Rate)
Endpoint domain: Mortality/survival
Primary endpoint: Positive stress test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Feasibility of fusion imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in circulating proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants Experiencing Adverse Events Defined as Dose-Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Vascular-Alzheimer's Disease Assessment Scale-Cognitive subscale (V-ADAS-cog)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinician's Interview-Based Impression of Change-Plus Version (CIBIC-Plus)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Blood Glucose Control Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Perioperative Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of EMI
Endpoint domain: Adverse events/effects
Primary endpoint: Composite measures based on radiotracer tissue uptake ratios and rates of metabolism in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Longer-term complications in patients surviving COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change From Baseline in Lung Clearance Index 2.5 (LCI2.5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: overall mortality rate at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of parastomal bulging
Endpoint domain: Adverse events/effects
Primary endpoint: Chemotherapy Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AUC0-tz for Empagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-tz for Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained clinical response (SCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cost of therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HCV Ab+ (Hepatitis C Virus antibody)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HBsAg+ (Hepatitis B surface Antigen)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HIV Ab+ (human immunodeficiency virus) antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cumulative Individual Irritation Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of volunteers with unsolicited vaccine-associated adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of volunteers with local or systemic vaccine reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of volunteers with vaccine-associated serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Objective cartilage repair measured by MRI scanning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline for VAS scores
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change from baseline of pain and functions scores on KOOS questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pharmacokinetics of bardoxolone methyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From Re-operation Due to Recurrent Severe Mitral Regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in C-DLQI (Children's Dermatology Life Quality Index) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Comprehensive Quality of Life (QOL) Measure for Facial and Truncal Acne (CompAQ) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percent Change in Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Jaw measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any death
Endpoint domain: Mortality/survival
Primary endpoint: Change in Aberrant Behavior Checklist - Social Withdrawal (ABC-SW) Subscale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Presence of plate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periodontal insertion level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average nocturia individual volume void
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Nocturnal functional bladder capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total urine production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in total score of the Menopause Rating Scale (MRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Device-related MACE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of autoimmune and cholestatic liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Third ventricle diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in uterine artery blood flow (Resistance Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Volumes of the Hippocampus, Thalamus and Amygdala
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Healed Femur Fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of Intima Media Thickness (IMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Feasibility to recruit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hair Regrowth Within the Scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Food Intake at 1 month using dietary assessment tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Food Intake at 1 month, Self-Report Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Aerobic Bacteria Microbial Count on Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Anaerobic Bacteria Microbial Count on Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Candidal Microbial Count on Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Learning curve of surgeon based on the duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Learning curve based on removed disc
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Learning curve based on the C-arm shot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of oral and pharyngeal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tissue thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Anatomic landmark position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vigilance outcome
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Motor outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Power (kilojoules)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma exacerbation relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Composite outcome of myocardial infarction, death, acute coronary syndrome, unplanned coronary revascularization, hospitalization for cardiovascular reason, stroke
Endpoint domain: Mortality/survival
Primary endpoint: LSAS-performance Subscale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Subjective Units of Distress Scale (SUDs)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Salivary Testosterone Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Extent of gingivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sputum Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall Response (OR) of the injected tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in pain severity assessed by the McGill Pain Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain-associated disability assessed by the Pain Disability Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants With Dose Limiting Toxicity (DLT) Events
Endpoint domain: Adverse events/effects
Primary endpoint: Successful early vein graft remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline in intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first negative test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of viral type detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Adherence to Initial Follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention